Business Wire

WA-PATTERN-COMPUTER

Share
Pattern Computer Discovers New and Novel Methods for Reducing Flight Delays

Pattern Computer,® Inc. (PCI) is excited to announce the discovery of new insights that can lead to significant reductions in the flights delays experienced across the United States.

According to the Federal Aviation Association (FAA)/Nextor, the estimated annual costs of delays, which includes direct costs to airlines and passengers, lost demand and indirect costs, in 2018 was $28 billion. Based on the Bureau of Transportation statistical data, 34% of all flights in 2018 experienced some type of departure delay and 18% of all flights experienced delays of 15 minutes or more, with an average delay of 66 minutes. The direct costs of those delays to airlines and passengers was $4.5 billion.

PCI’s team assembled a novel, integrated dataset which encompassed the FAA flight, aircraft and operational network data, and relevant US national weather data for the 7.2 million US commercial passenger flights in 2018.

Utilizing the Pattern Discovery Engine®, the PCI team was able to uncover a number of patterns underlying US commercial passenger flight delays. While many previous approaches focused on arrival delays, the PCI team chose to focus on flight departure delays as it more accurately reflects the operational efficiency of the individual airlines, as well as the airlines’ operational partnership with the FAA air traffic control facilities.

The most significant pattern, which was reflected as the top driver of delays in 11 of the 12 months, were flight departure delays due to weather factors along the route of travel, combined with the scheduled departure time (congestion). Together these two factors were the most consistent throughout the entirety of 2018. The flight leg for that day also played into this pattern in 10 of the 12 months as well – indicating that the cascading effect of flight delays continued to impact flights later in the day.

“When we used the Pattern Discovery Engine to understand the factors behind flight departure delays, we saw delays initiated by the FAA’s Traffic Management Initiatives due to en route weather as having created the most significant delays over the course of the year. The second most significant pattern was due to icing conditions at the departure airport, which also has cascading effects through the day for the impacted aircraft. A differentiating factor for Pattern Computer is that we do not see just one pattern; we see all the interrelated patterns in the dataset regarding a specific outcome in ranked order,” said Mark R. Anderson, CEO of Pattern Computer.

The newly discovered patterns indicate that most flight delays through the year were the results of significant weather events having regional limiting effects on the available flight routes. These large regional storms are typically predicted by the NOAA/FAA at least 48-72 hours in advance, airlines cancel flights ahead of the worst storms to avoid the high costs of long-delayed flights, including staffing costs, dissatisfied passengers, and crews cancelled due to duty-time expiration and required rest periods. While canceling flights is one option in reducing the costs of flight delays, the negative impact to customer satisfaction is high, and there is significant disruption to the airlines’ careful scheduling of crews, equipment and supporting staff. Too often the case is to carry on with the planned schedule and let the FAA determine how many planes are impacted as the weather event occurs. In many aspects, this is the same operating strategy as has been in effect for the past 4 decades.

“Due to the pandemic, the travel industry is facing a challenging period of uncertainty, but with that is the opportunity to improve operations, pricing, and offerings in a way that is future-ready. There is an opportunity to develop services tailored for the life styles, needs, and interests of business and leisure passengers alike. Post-pandemic, people are expecting a ‘new normal’ to emerge with many of the known patterns of life being different. Now is the time to introduce new capabilities, preparing for a post-pandemic swell in leisure travelers wishing to get out and travel,” said Bob Edwards, former CIO for United Airlines.

Without changes, the airlines will continue to bear substantial direct and indirect costs due to flight departure delays. But informed by these new Pattern discoveries, leading airlines could use technology, data and analytics combined with agility to create new solutions in the form of flexible scheduling, routing, pricing, and packaging to avoid these costs, which will only increase as the passenger loads begin to recover to their new normal, which may exceed the historical norms.

This work by Pattern Computer could allow informed, flexible scheduling. Dynamic load levels could be shifted and adjusted to the changing conditions, optimizing for costs, better utilizing available resources and resulting in more reliable schedules. Pattern is continually innovating and looking for ways to improve and optimize complex challenges in multiple industries, including the global airline industry, where new partnerships are now being sought.

The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws, and are based on current information and/or management's good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.

About Pattern Computer

Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.

While the company is currently applying its computational platform to air traffic operations, it is also making pattern discoveries for partners in several other sectors, including drug discovery and biomedical research, materials science, aerospace manufacturing, veterinary medicine, and finance.

For more information on Pattern Computer Inc., visit: www.patterncomputer.com
For more information about Mark Anderson, visit: www.patterncomputer.com/founders/

Copyright © 2021 Pattern Computer, Inc. All Rights Reserved. Pattern Computer Inc., and PCI are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye